CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Shortening overall treatment to 12 weeks of SIMEPREVIR plus pegylated-interferon/ribavirin according to early virologic response in treatment-naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis
DOI 10.1055/s-0035-1551766
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Ferenci, T Asselah, C Moreno, A Craxi, F Sanai, R Ryan, O Lenz, G Van Dooren, I Lonjon-Domanec, M Schlag, M Buti
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: HCV genotype 4 (GT4) is highly prevalent in the Middle East and Sub-Saharan Africa, and is expanding in Europe. To prevent disease progression, short and effective regimens are needed for these patients. This study aims to assess whether treatment with simeprevir+Peg-IFN/ribavirin can be shortened to 12 weeks, based on early viral kinetics, in patients with mild-to-moderate fibrosis. Design: Phase-3, open-labe…
Zitieren
Zitierempfehlung
P Ferenci, T Asselah, C Moreno, A Craxi, F Sanai, R Ryan, O Lenz, G Van Dooren, I Lonjon-Domanec, M Schlag, M Buti (2015) Shortening overall treatment to 12 weeks of SIMEPREVIR plus pegylated-interferon/ribavirin according to early virologic response in treatment-naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0035-1551766
Mit CareLit weiterarbeiten